drugset / Trial / NCT04939675

Modification of Epilepsy Screen Questionnaire and Treatment Feasibility Evaluation

NCT04939675

RandomizedParallel-groupOpen-labelTreatment

Summary

Atypical presentations in epilepsy may include confusion status, acute maniac or delirious condition, loss of cognitive ability such as speech, interaction skills, or other praxis. Current diagnosis of epilepsy did not address on definition of seizure. The new insights of seizure semiology and their treatment response, suggest the screen tool and diagnostic criteria of epilepsy can be revised. In this study, we have two aims. The first aim is to develop a screening questionnaire by adding new semiology of epilepsy, including abnormality in psychiatry, cognition, and sleep, and to test its accuracy. The second aim is to evaluate the benefits in cognition of anti-epileptic drug intervention in participants with positive screening results.

Timeline

Start
2021-07-01
Primary completion
2023-06-30
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 50 mg
Subject Levetiracetam Other / unclassified 500 mg
Subject Zonisamide Other / unclassified 100 mg

Indications